We are live on ! Find out more
BLUE

bluebird bio
BLUE

Delisted

BLUE was delisted on the 30th of May, 2025.

Back to rankings

67 hedge funds and large institutions have $236M invested in bluebird bio in 2013 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,100% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 1

1,451% more capital invested

Capital invested by funds: $15.2M → $236M (+$221M)

1,017% more funds holding

Funds holding: 6 → 67 (+61)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
67
Holders Change
+61
Holders Change %
+1,016.67%
% of All Funds
2.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
62
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$44.9M
2
Capital Research Global Investors
Capital Research Global Investors
California
+$29.6M
3
WRF
Waddell & Reed Financial
Kansas
+$25.8M
4
Jennison Associates
Jennison Associates
New York
+$17.4M
5
RCM
RA Capital Management
Massachusetts
+$13.4M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$1.25M
2
EEG
E.E. Geduld
-$452K
3
Ameriprise
Ameriprise
Minnesota
-$2.97K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$42.2M +$44.9M +120,981 New
Capital Research Global Investors
2
Capital Research Global Investors
California
$27.8M +$29.6M +79,670 New
WRF
3
Waddell & Reed Financial
Kansas
$24.3M +$25.8M +69,565 New
Jennison Associates
4
Jennison Associates
New York
$16.3M +$17.4M +46,769 New
RCM
5
RA Capital Management
Massachusetts
$12.6M +$13.4M +36,085 New
DM
6
Deerfield Management
New York
$11.4M +$12.1M +32,673 New
Franklin Resources
7
Franklin Resources
California
$9.16M +$9.74M +26,220 New
Ameriprise
8
Ameriprise
Minnesota
$8.71M -$2.97K -8 -0%
UBS AM
9
UBS AM
Illinois
$6.62M +$7.04M +18,943 New
O
10
OrbiMed
New York
$6M +$6.38M +17,177 New
RIM
11
RS Investment Management
California
$5.8M +$6.16M +16,598 New
PC
12
PointState Capital
New York
$5.39M +$5.73M +15,440 New
PHS
13
PFM Health Sciences
California
$5.33M +$5.67M +15,278 New
BFA
14
BlackRock Fund Advisors
California
$5.19M +$5.52M +14,868 New
BA
15
BlackRock Advisors
Delaware
$4.54M +$4.82M +12,988 New
WMSA
16
Weiss Multi-Strategy Advisers
New York
$4.45M +$4.73M +12,738 New
CCM
17
Camber Capital Management
Massachusetts
$4.04M – – –
AG
18
Artal Group
Luxembourg
$4.04M +$4.3M +11,580 New
BBA
19
Baker Bros. Advisors
New York
$3.01M +$3.2M +8,609 New
Vanguard Group
20
Vanguard Group
Pennsylvania
$2.83M +$3.01M +8,100 New
QF
21
QVT Financial
New York
$2.02M +$2.15M +5,790 New
Millennium Management
22
Millennium Management
New York
$1.75M +$1.86M +5,018 New
BIT
23
BlackRock Institutional Trust
California
$1.72M +$1.83M +4,924 New
State Street
24
State Street
Massachusetts
$1.53M +$1.63M +4,388 New
TRSOTSOK
25
Teachers Retirement System of the State of Kentucky
Kentucky
$1.48M +$1.57M +4,231 New
1
2 3

BLUE Hedge Fund Activity: Q3 2013 in Review

67 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q3 2013, worth a combined $236M — up 1,451% from $15.2M a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new BLUE positions and 1 closed out — a net gain of 61 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $44.9M. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.25M sold.

  • 67 institutional investors held bluebird bio (BLUE) as of Q3 2013, up from 6 in Q2 2013.
  • Funds reported $236M of bluebird bio stock for Q3 2013, up 1,451% quarter-over-quarter.
  • 62 funds opened new bluebird bio positions in Q3 2013 and 1 closed out, a net change of +61 holders.
  • The largest bluebird bio buyer in Q3 2013 was Fidelity Investments, an estimated $44.9M added.
  • The largest bluebird bio seller in Q3 2013 was Citadel Advisors, an estimated $1.25M sold.

Based on aggregated 13F filings for Q3 2013.